Evaluation of 18F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer

被引:117
作者
Hannah, A [1 ]
Scott, AM [1 ]
Tochon-Danguy, H [1 ]
Chan, JG [1 ]
Akhurst, T [1 ]
Berlangieri, S [1 ]
Price, D [1 ]
Smith, GJ [1 ]
Schelleman, T [1 ]
McKay, WJ [1 ]
Sizeland, A [1 ]
机构
[1] Austin & Repatriat Med Ctr, Ctr Positron Emiss Tomog, Heidelberg, Vic 3084, Australia
关键词
D O I
10.1097/00000658-200208000-00009
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective To prospectively evaluate the use of F-18-Fluorodeoxyglucose positron emission tomography (FDG-PET) in the initial staging of squamous cell head and neck carcinoma. Summary Background Data The status of cervical lymph nodes is an important prognostic factor and determinant of management approach in squamous cell head and neck cancer. Methods FDG-PET findings were compared with those of computed tomography (CT) before removal of the primary tumor and/or neck dissection. Histopathologic analysis was used as the gold standard for assessment of the sensitivity and specificity of these modalities. Results FDG-PET correctly identified the primary tumor in 35 of 40 patients in whom the site of the primary was known clinically and still present (sensitivity 88%). None of four unknown primaries were detected. Tumors not detected by FDG-PET were generally superficial, with depths of less than 4 mm. CT correctly identified 18 of the 35 primary tumors (sensitivity 51%). Eleven of 17 CT false-negative tumors were detected by FDG-PET. The sensitivity and specificity for the presence of metastatic neck disease on FDG-PET were 82% and 100%, respectively; those for CT were 81% and 81%, respectively. FDG-PET was true positive for metastatic neck disease in two of the three CT false-negative patients. Conclusions FDG-PET shows promise in the initial staging of head and neck cancer and provides additional accuracy to a conventional staging process using CT.
引用
收藏
页码:208 / 217
页数:10
相关论文
共 13 条
[1]  
BAILET JW, 1992, LARYNGOSCOPE, V102, P281
[2]  
BRAAMS JW, 1995, J NUCL MED, V36, P211
[3]   PET and [F-18]-FDG in oncology: A clinical update [J].
Conti, PS ;
Lilien, DL ;
Hawley, K ;
Keppler, J ;
Grafton, ST ;
Bading, JR .
NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (06) :717-735
[4]   EVALUATION OF CERVICAL LYMPH-NODE METASTASES IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
DON, DM ;
ANZAI, Y ;
LUFKIN, RB ;
FU, YS ;
CALCATERRA, TC .
LARYNGOSCOPE, 1995, 105 (07) :669-674
[5]  
Greven KM, 1999, CANCER, V86, P114, DOI 10.1002/(SICI)1097-0142(19990701)86:1<114::AID-CNCR16>3.0.CO
[6]  
2-E
[7]   FDG PET in head and neck cancer [J].
Keyes, JW ;
Watson, NE ;
Williams, DW ;
Greven, KM ;
McGuirt, WF .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1997, 169 (06) :1663-1669
[8]  
LAUBENBACHER C, 1995, J NUCL MED, V36, P1747
[9]  
MADISON MT, 1994, RADIOL CLIN N AM, V32, P163
[10]   A COMPARATIVE DIAGNOSTIC STUDY OF HEAD AND NECK NODAL METASTASES USING POSITRON EMISSION TOMOGRAPHY [J].
MCGUIRT, WF ;
WILLIAMS, DW ;
KEYES, JW ;
GREVEN, KM ;
WATSON, NE ;
GEISINGER, KR ;
CAPPELLARI, JO .
LARYNGOSCOPE, 1995, 105 (04) :373-375